Incidence Rates for Anal Carcinoma, Adenocarcinoma Have Increased Significantly
the Cancer Therapy Advisor take:
Incidence rates (IRs) of anal squamous cell carcinoma (SCC) and squamous carcinoma in situ (CIS) have significantly increased overtime, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
The authors of the study used data from the Surveillance, Epidemiology and End Results (SEER) Program to estimate age-adjusted anal cancer IRs by demographic and tumor characteristics from 2000 to 2011. Trends in annual percent changes and IRs from 1977 to 2011 were compared to those of rectal cancer.
Results showed females were associated with higher rates of SCC (rate ratio [RR]=1.45; 95% CI: 1.40, 1.50) and lower rates of ADC (RR=0.68; 95%CI: 0.62, 0.74) and squamous carcinoma in situ (CIS; RR=0.36; 95%CI: 0.34, 0.38) compared to males.
Furthermore, African Americans demonstrated lower rates of SCC (RR=0.82; 95% CI: 0.77, 0.87) and CIS (RR=0.90; 95% CI: 0.83, 0.98) but higher rates of ADC (RR=1.48; 95% CI 1.29-1.70) compared to non-Hispanic whites.
From 1992 to 2011, SCC IRs increased 2.9% per year, ADC IRs declined non-significantly, and CIS IRs increased 14.2% per year.
The authors noted similar trends were observed in SCC and ADC IRs across anal and rectal cancers.
Incidence rates of anal squamous cell carcinoma and squamous carcinoma in situ have significantly increased overtime.
Incidence rates (IRs) of anal squamous cell carcinoma (SCC) and squamous carcinoma in situ (CIS) have significantly increased overtime.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Role of miR-125a-5p Clarified in Bladder Cancer
- Bladder Cancer Clinical Features Linked to EGFR and HER-2 Expression
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- A Vegan Diet and Cancer
- The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear